Evidence · Trials · continued

Reading a supplementary appendix and finding the interesting part posts 91–93

Evidence › Trials open label discontinuation & dropout intention to treat estimand

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

n.ibarraTL212 Feb 2025#91

I would rather this thread reach "we do not know" about reading a supplementary appendix than reach a confident answer that nobody can support when asked.

14 likes 17mo

k.otieno_statsTL3Statistician13 Feb 2025#92

d.achebe, post #19: Reading a supplementary appendix has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time. Go to post

I read post #90 twice before replying, because I had assumed the opposite.

I changed my mind about reading a supplementary appendix after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.

28 likes in reply to #19 17mo

z.okonkwoTL214 Feb 2025#93

Taking post #92 at face value and following it one step further.

Composite endpoints should be read component by component. A composite driven entirely by its softest component is a different finding from one where the components move together.

I would want the raw data before agreeing with my own summary of it.

0 likes 17mo

This topic was referenced in

Second pass at: Trial registration and comparing the protocol with the paperEvidence › Trials · 34 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
About the Trials category Evidence › Trials randomised trial estimand intention to treat Pinned Wiki Individual randomised trials: design, population, endpoints, results, and limitations. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…	+6	10	27k	12mo
[2026 update] Reading a supplementary appendix and finding the interesting part Evidence › Trials estimand intention to treat open label surrogate endpoints On the subject in the title: Reading a supplementary appendix and finding the interesting part Working notes rather than a conclusion. Collecting what is known about Reading a supplementary appendix in one…	+39	44	8.2k	5mo
[2026 update] How to read a forest plot, properly, from scratch Evidence › Trials estimand discontinuation & dropout surrogate endpoints Solved How to read a forest plot, properly, from scratch — that is the question, and I have not found it answered plainly anywhere I have looked. Reading SURMOUNT-4 ( JAMA , 2024) for the population rather than the…	+49	53	643	19mo
How to read a forest plot, properly, from scratch Evidence › Trials randomised trial intention to treat surrogate endpoints estimand Solved The question in the title: How to read a forest plot, properly, from scratch I will give what I have already checked below so nobody repeats it. Reading STEP 4 ( JAMA , 2021) for the population rather than…	+73	81	17k	7mo
Primary endpoint hierarchies and why order matters — one year on Evidence › Trials surrogate endpoints discontinuation & dropout estimand randomised trial Solved On the subject in the title: Primary endpoint hierarchies and why order matters — one year on Working notes rather than a conclusion. A follow-up question about Primary endpoint hierarchies that I did not…	+56	61	37k	11h

Related topics — sharing the tags open label, discontinuation & dropout, intention to treat

Topic	Participants	Replies	Views	Activity
Journal club: STEP 8 and the fairness of the comparator dose Evidence › Journal club estimand number needed to treat journal club Journal club: STEP 8 and the fairness of the comparator dose — setting out what I have, and where I think it stops being reliable. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting; the…	+2	6	39k	12mo
The CagriSema phase 2 paper and what a fixed combination buys Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide effect size Posting this under the heading it deserves: The CagriSema phase 2 paper and what a fixed combination buys Everything below is what sits behind that. Working notes on cagrisema phase 2 paper rather than a…	+88	93	29k	11mo
Journal club: orforglipron phase 2 and the non-peptide question Evidence › Journal club journal club estimand randomised trial Journal club: orforglipron phase 2 and the non-peptide question Writing it up because I had to work it out twice and would rather nobody else did. Orforglipron phase 2, and specifically the version of it that…	+120	132	13k	1d
Second pass at: Reading a trial's population section before its results Evidence › Trials open label intention to treat estimand surrogate endpoints Solved Second pass at: Reading a trial's population section before its results Writing it up because I had to work it out twice and would rather nobody else did. Reading STEP 1 ( N Engl J Med , 2021) for the…		4	9.5k	10h
SURMOUNT-4 and what withdrawal data does and does not tell an individual Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme Solved SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…		4	42k	11mo